Dr. Jürgen Moll is the CSO and co-founder of iDEL Therapeutics GmbH. Embodying a true "drug hunter" mentality, he possesses extensive expertise in cancer research and preclinical development. His work focuses on advancing cancer cell-targeted and immuno-oncology assets across a variety of modalities, including small molecules, antibodies, and nanobodies.
Dr. Moll’s career is defined by a proven track record of progressing oncology targets from initiation to development. He has built long-term drug development experience across Top-20 Pharma companies – including Novartis, Pharmacia, Pfizer, Boehringer Ingelheim, and Sanofi – as well as leading biotech firms like Nerviano Medical Sciences. From 2022 to 2025, he served as CSO of Tessellate Bio. Highly regarded for his strategic insights, he frequently acts as a board member and consultant for prominent industry players such as BioNTech, Protai, and Gordion, among many others.
A dedicated contributor to the scientific community, Dr. Moll lectures at SUPBIOTECH University in Paris. He holds a strong publication and patent record, acts as a peer reviewer, and is a published author in the Nature Springer series.
Merging scientific excellence with deep business development skills, Dr. Moll leverages a vast international network to drive successful in-licensing, due diligence, and deal-making. His strong venture capital ties have led to landmark fundraising successes, including a €500M+ deal between Tessellate Bio and Boehringer Ingelheim in April 2025, alongside securing funding to propel iDEL Therapeutics forward. Throughout his endeavors, he remains committed to the principle that empowering and growing people is the ultimate factor for success.
